Improving Blood Pressure Management in Patients With Diabetes (SCRIP-HTN)
About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.
Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.
Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.
Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.
|Hypertension Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2||Behavioral: Lifestyle Counselling; Opinion Leader Influence Statements||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
|Official Title:||Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN|
- difference in change in systolic BP between the intervention and usual care groups [ Time Frame: 6 months ]
- change in antihypertensive therapy by new/additional hypertension medication or dosage increase between groups [ Time Frame: 6 months ]
- proportion of patients achieving goal BP of <130/80 mm Hg between groups [ Time Frame: 6 months ]
- proportion of patients that are prescribed an ACE inhibitor or angiotensin receptor antagonist between groups [ Time Frame: 6 months ]
|Study Start Date:||May 2005|
|Study Completion Date:||May 2007|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00374270
|University of Alberta|
|Edmonton, Alberta, Canada, T6G 2C8|
|Principal Investigator:||Ross T Tsuyuki, PharmD, MSc||University of Alberta|